Dural sealant enters European trial:
This article was originally published in Clinica
Executive Summary
Confluent Surgical has begun a single-site, European clinical trial of its sprayable synthetic sealant for reducing the rate of cerebrospinal fluid leakage in patients undergoing cranial and spinal surgical procedures. The sealant is indicated for use as an adjunct to standard methods of closure of the dura mater. The product is sprayed onto the tissue at the end of a surgical procedure. It forms a flexible, watertight seal, remains adhered to the tissue during the critical healing period and is then safely absorbed by the body, says the Waltham, Massachusetts firm.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.